Wednesday, December 09, 2009 12:03:46 PM
You have your FDA steps out of order.
Among other things, An NDA comes after Phase III and is the final step before FDA review and approval.
As you can see from the chart below, NNVC testing is in the infant stages.
Normally, it takes 5 - 8 years for final approval. Being that this is new technology, I expect it to take longer, just because the FDA is very cautious with new technology. And the fact that the treatment can be considered only a temporary cure, because after treatment, it is possible to be re-infected with the virus, as no antibodies are produced. Could be a big political problem when dealing with the FDA.
Among other things, An NDA comes after Phase III and is the final step before FDA review and approval.
As you can see from the chart below, NNVC testing is in the infant stages.
Normally, it takes 5 - 8 years for final approval. Being that this is new technology, I expect it to take longer, just because the FDA is very cautious with new technology. And the fact that the treatment can be considered only a temporary cure, because after treatment, it is possible to be re-infected with the virus, as no antibodies are produced. Could be a big political problem when dealing with the FDA.
Deeds, not creeds.
Recent NNVC News
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
